AffloVest Device Found To Improve Lung function Score in Adolescents with Cystic Fibrosis

AffloVest Device Found To Improve Lung function Score in Adolescents with Cystic Fibrosis

A new clinical study showed that AffloVest®, portable High Frequency Chest Wall Oscillation (HFCWO) vest, improved lung function scores in a cohort of adolescents with Cystic fibrosis. The study, entitled “An evidence-based study of adolescents with cystic fibrosis demonstrated that AffloVest® by International Biophysics contributed to improved lung function score,” reported the findings concerning the use of the AffloVest by a group of 5 cystic fibrosis patients over the course of several months, where the authors observed a real difference between the use of the device and older air-bladder technology high frequency chest wall oscillation (HFCWO) devices. The study was performed by Michael Cooper, an investigating clinician of Chicago, IL, which aims to achieve better long-term care control and quality of life for patients with chronic breathing disorders.

International Biophysics Corporation has been developing, manufacturing and marketing medical and surgical devices worldwide for more than 20 years. AffloVest is self-contained, portable, quiet, and functions with a rechargeable battery, giving patients complete freedom and mobility.   Mr. Cooper said in the news release that adolescents were using the AffloVest during a basketball game and while dancing, something that he never has seen.

The study consisted of reporting the lung function values using FEV1, parameter that measures the volume exhaled during the first second of a forced expiratory maneuver started from the level of total lung capacity, for the 5 patients before and after the therapy with AffloVest. This group of patients was previously using air bladder type HFCWO vests. There are several devices and variables that improve lung function scores, but normally they are lower than 10% and this value is suboptimal. Mr. Cooper observed 11.5% improvements in this group of patients, suggesting this device as a potential alternative therapy, especially for adolescents and college-aged patients with active lifestyles who want to cut down on the limitations and amount of time needed to use traditional breathing vest designs.

[adrotate group=”1″]

David Shockley, CEO of International Biophysics Corporation, the owner of AffloVest, stated, “We are pleased to see these enhanced lung function scores in Mr. Cooper’s CF patients.” He added that these findings strengthened the positive opinions received previously from other patients and clinicians over the last year. Shockley added that is not common to see research being performed without corporate funding and that Mr. Cooper truly cares about the quality of life of his patients.

Clinicians that have patients with lung diseases such as cystic fibrosis, bronchiectasis and neuromuscular diseases should be aware of the present clinical study.

 

 

2 comments

  1. D'Aun says:

    Actually, this article does NOT show that AffloVest improves lung function. Notice how there are no p-values, no control group, and that they only show you the data from 12 of the 25 patients in the (very small) sample group. In addition, these are adolescents, and they are measuring the volumes as total amount, not compared to their predicted values which change with age. When it does use the predicted values, there is only one value, not 2. When you grow older and/or taller (as the adolescents in this study are very likely to have done, especially since the tests were done 8 months apart for some patients), your lung volumes increase. If they had a control group, this would have shown that. The author purposely left out important data that would have shown the reader that AffloVest makes no significant difference in a patient’s lung function compared to any other therapy.

    Now, I actually like AffloVest. It’s one of my favorite HFCWO devices! I am just extremely disturbed that someone allowed a paper this ethically and scientifically flawed to be published anywhere.

    • Patricia Silva, PhD says:

      Hello D’Aun, in this particular study, Dr. Cooper only assessed the use of the AffloVest in 5 adolescents (between 14 and 18 years) during a period of 3-5 months. The study is not a clinical trial, and the results are based on Dr. Cooper’s observations when clinically assessing the 5 adolescents regarding any potential improvement in lung function.
      The following information is written on the original article: “The data described in this paper were collected independently by the clinician author and not at the direction of International Biophysics Corporation (IBC). All patients independently obtained an Afflovest by prescription from their physicians via their own insurance or private pay for their own personal use. Results were documented during routine clinical visits.”

Leave a Comment

Your email address will not be published. Required fields are marked *